As currently available data are derived from in-depth analyses of these relationships, future validation with prospective studies is needed to confirm the potential of circulating COMP as a biomarker for progression of liver fibrosis in post-operative BA patients. The gene discussed is COMP; the disease is breast angiosarcoma.